Answer
Tenofovir disoproxil in Efavirenz/Emtricitabine/Tenofovir disoproxil Glenmark may reduce bone mineral density and cause proximal renal tubulopathy associated with bone abnormalities such as osteomalacia, which can manifest as persistent or worsening bone pain and infrequently contribute to fractures.
Sources for this answer
- Efavirenz/Emtricitabine/Tenofovir disoproxil Glenmark 600 mg/ 200 mg/245 mg film-coated tabletsGlenmark Pharmaceuticals Europe Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 5Document updated
Sources checked